Protein detail

GLP2R

Glucagon-like peptide 2 receptor (GLP-2 receptor) (GLP-2-R) (GLP-2R)

Entry name GLP2R	UniProt ID O95838	EVMP confidence score 0.50
Supporting publications (n) 1	Transmembrane count 7	Protein classification FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins

EVMP confidence score

Annotation confidence score; open for threshold definitions.

Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40

Basic Information12

Protein Names

Glucagon-like peptide 2 receptor (GLP-2 receptor) (GLP-2-R) (GLP-2R)

Protein Class (3)

FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins

Protein Function (3)

G-protein coupled receptors:GPCRs excl olfactory receptors
G-protein coupled receptors:Family 2 (B) receptors
FDA approved drug targets:Biotech drugs

Transmembrane

174..198; Helical; Name=1; 211..235; Helical; Name=2; 262..285; Helical; Name=3; 300..321; Helical; Name=4; 340..362; Helical; Name=5; 387..405; Helical; Name=6; 418..438; Helical; Name=7

Transmembrane Count

Ensembl

ENSG00000065325

Entrez Gene Symbol

GLP2R

Gene Description

Glucagon like peptide 2 receptor

Chromosome

Position

9822206-9892099

Supporting publications (n)

EVMP confidence score

0.50

Fluorescence & Localization6

Tissue SpecificplacentaCell SpecificLymphatic endothelial cellsSingle-Nuclei Brain Specificendothelial cellSecretome LocationSecreted to bloodSecretome FunctionReceptor

Function & Pathway7

Protein Function (3)

G-protein coupled receptors:GPCRs excl olfactory receptors
G-protein coupled receptors:Family 2 (B) receptors
FDA approved drug targets:Biotech drugs

Cellular Component (2)

Molecular Function (3)

Biological Process (3)

KEGG

hsa04080 Neuroactive ligand-receptor interaction

Reactome (5)

Mediation Categories (2)

Clinical-translation mediationReceptor-signaling mediation

Relations & Evidence53

Ligand-Receptor Signaling (52)

52 records.

Category	Parent	Database	Transmitter	Receiver	Secreted	Plasma Membrane (Transmembrane)	Plasma Membrane (Peripheral)
transmembrane	transmembrane	Ramilowski_location	No	No	No	Yes	No
transmembrane	transmembrane	OmniPath	No	No	No	Yes	No
plasma_membrane	plasma_membrane	UniProt_location	No	No	No	Yes	No
plasma_membrane	plasma_membrane	Cellinker	No	No	No	Yes	No
plasma_membrane	plasma_membrane	OmniPath	No	No	No	Yes	No
plasma_membrane_transmembrane	plasma_membrane_transmembrane	HPMR	No	No	No	Yes	No
plasma_membrane_transmembrane	plasma_membrane_transmembrane	OmniPath	No	No	No	Yes	No
cell_surface	cell_surface	Surfaceome	No	No	No	Yes	No
cell_surface	cell_surface	connectomeDB2020	No	No	No	Yes	No
cell_surface	cell_surface	OmniPath	No	No	No	Yes	No

Page 4 of 6Previous Next

Isolation & Detection Technology (1)

1 record.

EV Isolation Method	Detection Method	Number of References	References
Differential UltracentrifugationSize Exclusion Chromatography	Mass spectrometryWestern blotting\|Flow cytometryWestern blotting	3	40730843 41307968 38207106

Sequence, Structure & Domains9

Sequences

Length

553

Mass

63,001

Sequence

MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVSIKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPSYLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQLMYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYSKRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLWPRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLKILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFIQLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKKLSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTMANTMEEILEESEI

3D Structural Models

Turn

300..302; 437..439

Helix

167..202; 209..238; 253..256; 259..287; 303..307; 312..324; 341..370; 376..394; 399..403; 412..436; 441..451

Beta Strand

290..292; 336..338

3D Structure

Electron microscopy (1)

Domain & Motif Annotations

Protein Families

G-protein coupled receptor 2 family

Sequence Similarities

Belongs to the G-protein coupled receptor 2 family.

Clinical Relevance6

Disease Involvement

FDA approved drug targets

Related Diseases (5)

Bowel habit change Digestive system disease Indeterminate colitis Low bone mass disorder Neonatal malabsorption syndrome

Biomarker

Phase 2; Investigative; Phase 1; Approved

Drug Targets

FDA approved drug targets

Drugs (5)

TEDUGLUTIDE FE 203799 NULL GLEPAGLUTIDE ELSIGLUTIDE

Antibody (2)

CAB022690 HPA049244

Supporting Publications1

PMID	Title	Abstract
39318865	Stem Cell-Derived Exosomes as a Therapeutic Option for Spinal Cord Injuries; a Systematic Review and Meta-Analysis.	Additionally, MSC-derived exosome administration significantly increased the expression of the anti-inflammatory interleukin (IL)-10 and IL-4 (p<0.001 and p=0.001, respectively) and decreased the expression of the inflammatory IL-1b, IL-6, and TNF-a (p<0.0001). The administration of MSC-derived exosomes enhanced the expression of beta-tubulin III, NF200, and GAP-43, and increased the number of NeuN-positive and Nissl-positive cells, while reducing the expression of glial fibrillary acidic protein (p<0.0001).